Evaluation of health-related quality of life in hemolytic uraemic syndrome patients treated with eculizumab: a systematic evaluation on basis of EMPRO

Background: Hemolytic uraemic syndrome (HUS) is progressive renal failure disease and determination of their quality of life (QoL) on the basis of patient-reported outcomes (PROs) are becoming increasingly important in the economic evaluations for its treatment with eculizumab (ECU). Aim: To perform...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukherjee, Anwesha A., Kandhare, Amit D., Bodhankar, Subhash L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6014301/
https://www.ncbi.nlm.nih.gov/pubmed/29363392
http://dx.doi.org/10.1080/0886022X.2018.1427110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6014301/
https://www.ncbi.nlm.nih.gov/pubmed/29363392
http://dx.doi.org/10.1080/0886022X.2018.1427110

Ejemplares similares